Google
ANAB Stock Price & Analysis — Anaptysbio Inc (Healthcare >> Biotechnology)
ANAB FAQ
What is ANAB's P/E ratio?
Anaptysbio Inc (ANAB) currently trades at a P/E ratio of 24.41.
What is ANAB's ROE?
Anaptysbio Inc reports a Return on Equity (ROE) of -210.14%.
What is ANAB's dividend yield?
Anaptysbio Inc offers a dividend yield of 0.00%.
What is ANAB's Quality Score?
Our AI rates ANAB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANAB?
Our AI Timing Score for ANAB is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANAB belong to?
Anaptysbio Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
ANAB AI Analysis Summary
Our AI summary for ANAB: Anaptysbio Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 24.41, ROE of -210.14%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 53.66
Price
1.47
(2.74%)
Day Change
|
|
|---|
ANAB, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 53.66 |
| PBV / Sector |
123.94 / 44,219.29
|
| Earning Per Share | -0.91 |
| PE / Sector |
24.41 / 19.28
|
| PEG or PE/Growth / Sector |
-0.98 / 1.23
|
| Average 1M Daily Value |
41.88 M
GREAT
|
| Average 1W Daily Value |
29.96 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:08 |
| Symbol | ANAB |
| Name | ANAPTYSBIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,579.91 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
Phone: 858 362 6295
Website: https://www.anaptysbio.com
Employees: 104
Sector: Healthcare >> Biotechnology
Description: AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap